Meloxicam/Rizatriptan (Symbravo) vs Sumatriptan (Tosymra)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline

Meloxicam/Rizatriptan (Symbravo)

Marketed by Axsome Therapeutics

Approved in Migrainesmall molecule
Reliable signal

NCT03896009 · Phase 3 · completed

The trial was a large, randomized, double-blind, placebo- and active-controlled study with 1,594 participants. Both prespecified primary clinical endpoints were statistically significant in favor of the meloxicam/rizatriptan combination versus placebo: 2-hour headache pain freedom and absence of the most bothersome symptom.

Reported efficacy

Long-term Safety of Chronic Intermittent Use of AXS-07 (Up to 12 months): Long-term Safety of Chronic Intermittent Use of AXS-07 (Up to 12 months): AXS-07 — Subjects with any TEAEs: 293 Participants; Subjects with suspected to be drug-related TEAEs: 118 Participants; Subjects with serious TEAEs: 8 Participants; Subjects with TEAEs that led to drug withdrawal: 10 Participants; Subjects with TEAEs that led to withdrawal from study: 13 Participants; Subjects with TEAEs that resulted in death: 0 Participants (not_applicable)

Result source: NCT04068051

Sumatriptan (Tosymra)

Marketed by Tonix Pharmaceuticals and partners

Approved in Migrainesmall molecule
Weak signal

NCT02279082 · Phase 3 · completed

This was a single-arm, open-label study of 167 participants with no randomization, blinding, or comparator arm. Its primary endpoint was the number of participants with treatment-emergent adverse events, reported in 120 participants over six months, so the study provides descriptive safety information but cannot establish comparative safety or treatment efficacy.

Reported efficacy

Number of Participants With Treatment Emergent Adverse Events (6 months): Number of Participants With Treatment Emergent Adverse Events (6 months): DFN-02 120 Participants (not_applicable)

Result source: NCT02279082

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Meloxicam/Rizatriptan (Symbravo): registry results are on file for Migraine, but their comparison mappings are not yet available.

Sumatriptan (Tosymra): registry results are on file for Migraine, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Meloxicam/Rizatriptan (Symbravo)'s landscape · Sumatriptan (Tosymra)'s landscape